DTC
Deep Track Capital Portfolio holdings
AUM
$3.11B
This Quarter Return
-15.04%
1 Year Return
+13.6%
3 Year Return
+265.73%
5 Year Return
–
10 Year Return
–
AUM
$1.45B
AUM Growth
+$1.45B
(-6.6%)
Cap. Flow
+$232M
Cap. Flow
% of AUM
16.05%
Top 10 Holdings %
Top 10 Hldgs %
49.78%
Holding
57
New
6
Increased
22
Reduced
11
Closed
6
Top Buys
| 1 |
BioMarin Pharmaceuticals
BMRN
|
$54.2M |
| 2 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$42.9M |
| 3 |
Nuvation Bio
NUVB
|
$33.4M |
| 4 |
Nurix Therapeutics
NRIX
|
$30.9M |
| 5 |
Acadia Pharmaceuticals
ACAD
|
$24.4M |
Top Sells
| 1 |
Alnylam Pharmaceuticals
ALNY
|
$75.7M |
| 2 |
Keros Therapeutics
KROS
|
$17.7M |
| 3 |
SAGE
Sage Therapeutics
SAGE
|
$16.3M |
| 4 |
Enanta Pharmaceuticals
ENTA
|
$14.1M |
| 5 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
$9.25M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
GBT
1
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $117M | 7.66% | 3,646,690 +1,342,007 | +58% | +$42.9M |
|
2
NovoCure
NVCR
$1.38B
| $93.2M | 6.13% | 1,341,300 +341,300 | +34% | +$23.7M |
|
3
Travere Therapeutics
TVTX
$1.56B
| $86.8M | 5.7% | 3,580,700 +446,197 | +14% | +$10.8M |
|
4
Jazz Pharmaceuticals
JAZZ
$7.75B
| $78M | 5.13% | 500,000 -17,051 | -3% | -$2.66M |
|
5
Kura Oncology
KURA
$686M
| $67.8M | 4.46% | 3,697,969 +285,969 | +8% | +$5.24M |
|
6
Madrigal Pharmaceuticals
MDGL
$9.76B
| $64.8M | 4.26% | 905,000 +119,000 | +15% | +$8.52M |
|
|
KDNY
7
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $60M | 3.94% | 3,430,110 +430,110 | +14% | +$7.52M |
|
|
8
BioMarin Pharmaceuticals
BMRN
$11.2B
| $54.2M | 3.56% | +654,365 | New | +$54.2M |
|
9
Fate Therapeutics
FATE
$120M
| $50M | 3.29% | 2,018,005 +18,005 | +0.9% | +$446K |
|
|
BCYC
10
Bicycle Therapeutics
BCYC
$511M
| $48.7M | 3.2% | 2,900,000 +1,044,007 | +56% | +$17.5M |
|
11
Beam Therapeutics
BEAM
$1.66B
| $48.4M | 3.18% | 1,250,000 +486,250 | +64% | +$18.8M |
|
|
ISEE
12
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $43.3M | 2.85% | 4,500,000 | – | – |
|
|
AGEN
13
Agenus
AGEN
$133M
| $43.1M | 2.84% | 22,241,417 +8,242,926 | +59% | +$16M |
|
14
Esperion Therapeutics
ESPR
$448M
| $38.2M | 2.51% | 6,000,000 | – | – |
|
15
Repare Therapeutics
RPTX
$71.7M
| $37.9M | 2.49% | 2,707,662 +43,645 | +2% | +$611K |
|
|
16
Nuvation Bio
NUVB
$1.02B
| $37.2M | 2.44% | 11,471,281 +10,315,789 | +893% | +$33.4M |
|
17
Immunovant
IMVT
$2.56B
| $36.9M | 2.42% | 9,455,000 +2,230,387 | +31% | +$8.7M |
|
18
Nkarta
NKTX
$151M
| $34.7M | 2.28% | 2,814,844 +701,049 | +33% | +$8.64M |
|
|
19
Nurix Therapeutics
NRIX
$714M
| $30.9M | 2.03% | +2,436,164 | New | +$30.9M |
|
|
FMTX
20
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $27.9M | 1.83% | 4,050,000 +2,390,294 | +144% | +$16.5M |
|
|
TCDA
21
DELISTED
Tricida, Inc. Common Stock
TCDA
| $26.4M | 1.74% | 2,732,117 +79,424 | +3% | +$769K |
|
|
22
Acadia Pharmaceuticals
ACAD
$4.38B
| $24.4M | 1.61% | +1,733,130 | New | +$24.4M |
|
23
Dyne Therapeutics
DYN
$1.92B
| $24M | 1.58% | 3,500,000 | – | – |
|
24
4D Molecular Therapeutics
FDMT
$288M
| $21.9M | 1.44% | 3,140,000 +691,800 | +28% | +$4.83M |
|
|
25
Keros Therapeutics
KROS
$618M
| $20.4M | 1.34% | 739,528 -640,778 | -46% | -$17.7M |
|